This article presents a rare case of invasive aspergillosis induced by RET-TKIs in the treatment of RET fusion-positive NSCLC, suggesting that clinicians should pay attention to identifying ADRs, opportunistic infections, and tumor progression throughout the antitumor targeted therapy so as not to delay antitumor treatment. The gene discussed is RET; the disease is non-small cell lung carcinoma.